Cowen & Co. analyst Steven Mah upgrades Absci (NASDAQ:ABSI) from Market Perform to Outperform.
Barclays Initiates Coverage On Tandem Diabetes Care with Overweight Rating, Announces Price Target of $75
Barclays analyst Matt Miksic initiates coverage on Tandem Diabetes Care (NASDAQ:TNDM) with a Overweight rating and announces Price Target of $75.